Hepatocellular Carcinoma
📧 Sign up to get email alerts when something new happens for Hepatocellular Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma [Phase 2]
Phase 2 trial of abemaciclib plus nivolumab in hepatocellular carcinoma was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma [Phase 1, Phase 2]
Phase 1/2 trial updating safety and bioactivity of ipilimumab plus nivolumab before liver resection in hepatocellular carcinoma.
-
CLINICAL_TRIALS trial_result · 2022-12-09Clinical Trial Update: HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study [Phase 3]
Phase 3 trial comparing HAIC with one-day FOLFOX versus two-day FOLFOX for unresectable hepatocellular carcinoma; currently recruiting non-i…
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma [Phase 2]
Phase 2 trial evaluating regorafenib combined with nivolumab in unresectable hepatocellular carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: Low-dose Y90 Treatment Planning for HCC [NA]
A completed clinical trial investigating low-dose Yttrium-90 treatment planning for hepatocellular carcinoma (HCC) with results posted in 20…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2022-11-30Clinical Trial Update: Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors [Phase 4]
Clinical trial update comparing propofol-based total intravenous anesthesia versus sevoflurane anesthesia for long-term outcomes after elect…
-
CLINICAL_TRIALS trial_result · 2022-11-29Clinical Trial Update: Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]
Clinical trial updates on toripalimab combined with donafenib for advanced hepatocellular carcinoma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2022-11-28Clinical Trial Update: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors [Phase 2]
A Phase 2 clinical trial evaluating cabozantinib-s-maleate in pediatric patients with recurrent, refractory, or newly diagnosed sarcomas, Wi…
-
CLINICAL_TRIALS trial_result · 2022-11-17Clinical Trial Update: Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy [Phase 1, Phase 2]
A clinical trial update assessing safety and efficacy of Bifidobacterium therapy in patients with advanced hepatocellular carcinoma undergoi…
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating a combination therapy of HAIC, sintilimab, and bevacizumab for advanced hepatocellular carcinoma.
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: TACE Combined With Lenvatinib and Sintilimab for Advanced HCC [Phase 2]
Phase 2 trial update evaluating the combination of TACE with lenvatinib and sintilimab for non-resectable hepatocellular carcinoma.
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC [Phase 2]
A Phase 2 clinical trial comparing regorafenib plus sintilimab versus regorafenib alone as second-line therapy for non-resectable hepatocell…
-
FDA approval · 2022-11-09FDA Approved: SORAFENIB — Original Application (Yabao Pharmaceutical Co., Ltd. Beijing)
FDA approved a generic sorafenib product from Yabao Pharmaceutical Co., Ltd. Beijing (ANDA 209050). The approval covers the same indications…
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC [Phase 3]
Phase 3 trial comparing lenvatinib plus I-125 seed brachytherapy versus lenvatinib alone for TACE-refractory hepatocellular carcinoma (non-r…
-
CLINICAL_TRIALS trial_result · 2022-11-08Clinical Trial Update: HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients [Phase 2]
Phase 2 trial update for Holmium-166 radioembolization (HEPAR Primary) in patients with hepatocellular carcinoma, including non-resectable d…
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy [Phase 2]
Phase 2 trial evaluating erlotinib plus bevacizumab as second-line therapy for hepatocellular carcinoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-11-02Clinical Trial Update: A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]
Phase Ib/II trial evaluating safety and efficacy of QL1706 in patients with advanced hepatocellular carcinoma is ongoing and status is unkno…
-
CLINICAL_TRIALS trial_result · 2022-10-17Clinical Trial Update: HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC [Phase 2]
Phase 2 trial comparing HAIC+Lenvatinib+Tislelizumab to D-TACE+Lenvatinib+Tislelizumab for unresectable hepatocellular carcinoma is ongoing …
-
CLINICAL_TRIALS trial_result · 2022-10-17Clinical Trial Update: Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of Envafolimab and Lenvatinib with TACE for unresectable locally advanced hepatocellular…
-
CLINICAL_TRIALS trial_result · 2022-10-13Clinical Trial Update: TACE Combined With Sorafenib and Tislelizumab for Advanced HCC [Phase 2]
Phase 2 trial update evaluating the combination of TACE with sorafenib and tislelizumab for advanced non-resectable hepatocellular carcinoma…
-
CLINICAL_TRIALS trial_result · 2022-09-29Clinical Trial Update: Thermal Ablation Followed by Immunotherapy for HCC [Phase 1, Phase 2]
Clinical trial update exploring thermal ablation followed by immunotherapy for non-resectable hepatocellular carcinoma in Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2022-09-26Clinical Trial Update: TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma [Phase 2]
Phase 2 trial updating the combination of transarterial chemoembolization (TACE) with lenvatinib and microwave ablation (MWA) for locally ad…
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer [Phase 2]
Phase 2 clinical trial evaluating the combination of transarterial chemoembolization (TACE) with camrelizumab and apatinib for advanced hepa…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients [Phase 2]
Phase 2 clinical trial evaluating neoadjuvant lenvatinib combined with transarterial chemoembolization (TACE) for transplant-eligible patien…
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence [Phase 2]
Phase 2 trial investigating donafenib plus tislelizumab as adjuvant therapy for hepatocellular carcinoma at high risk of recurrence.